Sage Therapeutics (NASDAQ:SAGE) Rating Reiterated by Wedbush

Sage Therapeutics (NASDAQ:SAGE)‘s stock had its “neutral” rating reiterated by Wedbush in a research note issued on Wednesday, Benzinga reports. They currently have a $24.00 target price on the biopharmaceutical company’s stock. Wedbush’s price target suggests a potential upside of 84.12% from the stock’s current price.

Other equities analysts have also issued reports about the company. Royal Bank of Canada boosted their price target on Sage Therapeutics from $21.00 to $26.00 and gave the stock a “sector perform” rating in a research report on Thursday, February 15th. Bank of America lowered Sage Therapeutics from a “neutral” rating to an “underperform” rating and cut their target price for the company from $24.00 to $14.00 in a research report on Wednesday. HC Wainwright reaffirmed a “neutral” rating and issued a $28.00 target price on shares of Sage Therapeutics in a research report on Wednesday. StockNews.com raised Sage Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, February 15th. Finally, Morgan Stanley upped their target price on Sage Therapeutics from $20.00 to $22.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 28th. One analyst has rated the stock with a sell rating, fourteen have given a hold rating and three have assigned a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $39.28.

Sage Therapeutics Stock Performance

Sage Therapeutics stock opened at $13.04 on Wednesday. The stock’s 50 day moving average price is $20.06 and its 200 day moving average price is $20.96. The firm has a market capitalization of $783.53 million, a PE ratio of -1.44 and a beta of 0.86. Sage Therapeutics has a one year low of $10.92 and a one year high of $59.99.

Sage Therapeutics (NASDAQ:SAGE) last released its quarterly earnings results on Wednesday, February 14th. The biopharmaceutical company reported ($0.55) EPS for the quarter, topping the consensus estimate of ($1.28) by $0.73. The firm had revenue of $77.97 million for the quarter, compared to analyst estimates of $60.15 million. Sage Therapeutics had a negative return on equity of 54.41% and a negative net margin of 626.32%. Sage Therapeutics’s revenue for the quarter was up 2621.5% on a year-over-year basis. During the same period in the previous year, the company posted ($2.47) EPS. On average, analysts forecast that Sage Therapeutics will post -6.06 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the stock. Hennion & Walsh Asset Management Inc. grew its stake in Sage Therapeutics by 8.2% during the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 66,567 shares of the biopharmaceutical company’s stock worth $1,247,000 after buying an additional 5,068 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund grew its stake in Sage Therapeutics by 1,049.2% during the 4th quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 201,107 shares of the biopharmaceutical company’s stock worth $4,358,000 after buying an additional 183,607 shares during the last quarter. Vanguard Group Inc. grew its stake in Sage Therapeutics by 2.1% during the 4th quarter. Vanguard Group Inc. now owns 5,319,360 shares of the biopharmaceutical company’s stock worth $115,271,000 after buying an additional 111,358 shares during the last quarter. Fisher Asset Management LLC grew its stake in Sage Therapeutics by 8.1% during the 4th quarter. Fisher Asset Management LLC now owns 431,925 shares of the biopharmaceutical company’s stock worth $9,360,000 after buying an additional 32,306 shares during the last quarter. Finally, Goldman Sachs Group Inc. grew its stake in Sage Therapeutics by 52.2% during the 4th quarter. Goldman Sachs Group Inc. now owns 476,506 shares of the biopharmaceutical company’s stock worth $10,326,000 after buying an additional 163,400 shares during the last quarter. 99.22% of the stock is currently owned by institutional investors.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.